Document Detail

A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
MedLine Citation:
PMID:  17551299     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Radiation dose escalation is limited by the high incidence of pulmonary and esophageal toxicity, leading to calls for the omission of elective nodal irradiation (ENI) and the willingness to use involved-field irradiation (IFI) in patients with nonsmall cell lung cancer (NSCLC). METHODS AND MATERIALS: A total of 200 eligible patients with inoperable stage III NSCLC were treated with concurrent chemoradiotherapy and randomized into either an IFI or ENI arm. A total of 4 to 6 cycles of cisplatin-based chemotherapy were delivered, and concurrent radiotherapy was started after the second cycle of chemotherapy. Three-dimensional conformal radiotherapy was delivered in once-daily fractions of 1.8 to 2 Gy to 68 to 74 Gy for IFI or 60 to 64 Gy for ENI. RESULTS: Patients in the IFI arm achieved better overall response rate (90% vs. 79%, P = 0.032) and better 5-years local control rate (51% vs.36%, P = 0.032) than those in the ENI arm. The radiation pneumonitis rate in patients with IFI was lower than in patients with ENI (17% vs. 29%, P = 0.044), and similar trends appeared in the radiation esophagitis, myelosuppression, and radiation pericarditis between 2 study arms, although not significantly. The 1-, 2-, and 5-year survival rates were 60.4%, 25.6%, and 18.3% for the ENI arm and 69.9%, 39.4%, and 25.1% for the IFI arm, respectively. Only the 2-year survival rates were statistically significant (P = 0.048). CONCLUSION: IFI arm achieved better overall response and local control than ENI arm, and it allowed a dose of 68 to 74 Gy to be safely administered to patients with inoperable stage III NSCLC. Outcome improvement can be expected by conformal IFI combined with chemotherapy for stage III NSCLC.
Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Related Documents :
7838039 - Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children olde...
12582429 - Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia i...
15211599 - Adjusting for differential proportions of second-line treatment in cancer clinical tria...
10458219 - Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia...
20522709 - P-glycoprotein inhibition using valspodar (psc-833) does not improve outcomes for patie...
16721739 - Response to intraarterial induction chemotherapy: a prognostic parameter in oral and or...
22768439 - What is the role of field-directed therapy in the treatment of actinic keratosis? part ...
3492259 - Interferon therapy of non-hodgkin's lymphoma.
16321429 - Small cell of the ovary, hypercalcemic type -- analysis of combined experience and reco...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  30     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-06     Completed Date:  2007-07-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-44     Citation Subset:  IM    
Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / pathology,  therapy*
Cisplatin / therapeutic use*
Combined Modality Therapy
Lung Neoplasms / pathology,  therapy*
Lymphatic Metastasis / radiotherapy
Middle Aged
Neoplasm Staging
Prospective Studies
Radiotherapy, Conformal
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Next Document:  Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment...